Oric Pharmaceuticals (ORIC) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Oric Pharmaceuticals

NasdaqGS•Healthcare•Biotechnology

$12.62-0.24(-0.02%)Pre-market

Market Cap

$1.35B

P/B

3.6x

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

How this company scores

WeakMetricSide Score: 31/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Profitability (2/25).

Profitability2/25

Growth6/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality8/25

Strengths

Interest easily coveredNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/B · 3.6x5y range 0.6x – 3.6x

Currently above its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $1.35B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $0
Q. Revenue: $0
TTM EBITDA: $-154.40M
TTM Op. Income: $-156.14M
Q. Op. Income: $-45.30M
TTM Net Income: $-140.35M
Q. Net Income: $-41.49M
EPS: $-0.38
Shares Out.: $108.01M

$0 in TTM revenue was flat at zero YoY, reaching $0 last quarter. TTM EBITDA of $-154.40M and TTM operating income of $-156.14M show growth is flowing through to the bottom line. However, net income is negative at $140.35M — growth is not yet reaching the bottom line.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: N/A
Op. Margin: -4529600000.0%
Net Margin: -4149200000.0%

Op. margin of -4529600000.0% is down 623200000.0% YoY — costs are rising relative to revenue. Net margin at -4149200000.0% Across the last 8 quarters, operating margin has fallen for 2 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: N/A
P/B Ratio: 3.6x

P/S of 0.0x and P/B of 3.6x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $404.69M
Cash: $37.48M
Long-Term Debt: N/A
Book Value: $381.26M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-31.61M
TTM Free Cash Flow: $-112.26M
FCF Margin: N/A
FCF / Net Income: 0.8

TTM FCF of $-112.26M on $-31.61M in operating cash flow. The FCF / Net Income ratio of 0.8x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 7% — a weakening trend.